Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Emergent BioSolutions Inc.NYSE: EBS

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow growth accelerates

Q1 FY2026 financing cash flow of $11.4M (cash outflow) rose 2750.0% year over year, ahead of the -36.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 90.0% from the prior quarter.

Context

  • Financing cash flow amounted to 18.4% of revenue in FY2025, up 0.2 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +2750.0% holds above the trailing-twelve-month pace of -36.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11.4M-90.0% QoQ
Last fiscal yearDec 2025
-$136.6M-28.1% YoY
LTMMar 2026
-$147.6M-36.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2750.0%——
1 year-28.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(136.6M) USD
Year-over-year change
+28.1%

Financing Cash Flow vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -36.1% is the 9th highest of 11, against a peer median of +13.2%.
  • Financing cash flow amounts to 21.8% of revenue for EBS, versus a peer median of 12.1%.
EBS Competitors
Financing Cash Flow for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CMPSCOMPASS Pathways plcLTM Mar 2026$362.11M USD+157.4%+413.4%—
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$256.78M USD-1.3%+662.8%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$226.9M USD+360.2%——
EBSEmergent BioSolutions Inc.LTM Mar 2026$147.6M USD-36.1%—21.8%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$86.39M USD+284.0%+107.0%171.9%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$59.9M USD+615.4%+3.5%14.3%
SNDLSNDL Inc.LTM Mar 2026CA$50.85M CAD-20.7%+9.2%5.4%
SIGASIGA Technologies, Inc.LTM Mar 2026$44.12M USD+1.5%-1.8%47.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$35.52M USD-226.0%+99.1%6.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$10.8M USD+25.0%-54.9%3.6%
PRTAProthena Corporation plcLTM Mar 2026$7.03M USD-1150.0%—12.1%
Peer median (excluding EBS) —+13.2%+54.2%12.1%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income230.9M(211.6M)(760.5M)(190.6M)52.6M
Depreciation & Amortization123.8M143.3M125.1M108.8M95.8M
Deferred Income Tax46.9M(28.6M)(8.9M)(5.5M)(4M)
Stock-Based Compensation42.4M45.1M23.1M18M16.2M
Change in Working Capital(156.4M)(2.1M)(70.3M)88.7M(22.4M)
Accounts Receivables(48.2M)118.1M(21.6M)(24.4M)25.5M
Inventory(44M)(57.1M)600K(24.5M)(30.3M)
Accounts Payables(2.5M)(14M)10.6M(33M)(8.4M)
Other Working Capital(61.7M)(49.1M)(59.9M)170.6M(9.2M)
Other Non-Cash Items33.5M19.8M485.2M39.3M32.4M
Operating Cash Flow321.1M(34.1M)(206.3M)58.7M170.6M
Capital Expenditures(225M)(115.8M)(51.6M)(22.9M)(13.8M)
Acquisitions (Net)00270.2M00
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities0(265.5M)(6.3M)148.1M83.2M
Investing Cash Flow(225M)(381.3M)212.3M125.2M69.4M
Debt Repayment(35.9M)564.2M(543.4M)(198.4M)(112.5M)
Common Stock Issued008.4M9.3M2.2M
Common Stock Repurchased(106M)(82.1M)00(24.9M)
Dividends Paid00000
Other Financing Activities900K(900K)(700K)(900K)(1.4M)
Financing Cash Flow(141M)481.2M(535.7M)(190M)(136.6M)
Effect of Forex Changes(300K)500K(1.2M)0100K
Net Change in Cash(45.2M)66.3M(530.9M)(6.1M)103.5M
Free Cash Flow96.1M(149.9M)(257.9M)35.8M156.8M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.